Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The intricacies of cellular signaling pathways are central to understanding and treating diseases like cancer. The mTOR pathway, a critical regulator of cell growth and metabolism, is a prime target for novel cancer therapies. NINGBO INNO PHARMCHEM CO.,LTD. provides essential research chemicals like AZD2014, enabling scientists to delve into the precise mechanisms of action of these advanced therapeutics.
AZD2014 is recognized for its potent and selective inhibition of both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). This dual inhibition strategy is a significant advancement over therapies that target only one component of the pathway. The mTOR pathway is a complex signaling network that influences protein synthesis, cell growth, proliferation, metabolism, and survival. Dysregulation of this pathway is implicated in a wide array of cancers, making mTOR inhibitors highly sought after in oncology research.
The scientific literature details the specific targets and mechanisms through which AZD2014 exerts its effects. With an IC50 value for mTOR inhibition reported at a mere 2.8 nM, AZD2014 demonstrates exceptional potency. Its ability to inhibit both mTORC1 and mTORC2 addresses the cellular adaptive responses that can limit the effectiveness of single-target inhibitors. For example, while rapamycin inhibits mTORC1, cancer cells can compensate by activating mTORC2. AZD2014 circumvents this by simultaneously blocking both complexes.
The biological consequences of this dual inhibition are far-reaching. Studies have shown that AZD2014 effectively induces apoptosis (programmed cell death), triggers autophagy (a cellular self-degradation process), and promotes cell cycle arrest in cancer cells. These effects collectively lead to a significant suppression of cancer cell proliferation. This multifaceted action makes AZD2014 a compelling subject for research into new cancer treatments.
Furthermore, research has explored the interaction of AZD2014 with other therapeutic agents. Its synergistic effect when combined with inhibitors of Bruton's tyrosine kinase (BTK) in certain lymphomas, and its ability to enhance the radiosensitivity of glioblastoma cells, highlight its versatility. For researchers interested in purchasing AZD2014, these findings underscore its potential as a key component in next-generation combination therapies.
NINGBO INNO PHARMCHEM CO.,LTD. is committed to advancing scientific understanding by supplying high-quality AZD2014. By providing access to this sophisticated dual mTOR inhibitor, the company supports critical research into the precise mechanisms by which these compounds operate, paving the way for innovative cancer drug discovery and development.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
